Table 1 Demographic characteristics of the study patients with HIV infection
Overall study patients | Use of non-HIV medications | ||||
|---|---|---|---|---|---|
Total | With PDDI | Without PDDI | p-value | ||
Number of patients | 71 | 51 | 21 | 30 | – |
Age (years), median (range) | 45 (21–79) | 46 (21–79) | 45 (21–79) | 49.5 (28–72) | 0.250 |
Male | 67 (94.4) | 47 (92.2) | 19 (90.5) | 28 (93.3) | 1.000 |
Prior AIDS diagnosis, n (%) | 21 (29.6) | 15 (29.4) | 6 (28.6) | 9 (30.0) | 1.000 |
Time since diagnosis HIV (years), median (range) | 7 (1–29) | 8 (1–20) | 9 (1–17) | 7 (1–20) | 0.901 |
HCV co-infection, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
HBV co-infection (HBs-antigen positive), n (%) | 5 (7.0) | 4 (7.8) | 1 (4.8) | 3 (10.0) | 0.634 |
HIV-RNA < 50 copies/mL, n (%) | 70 (98.6) | 50 (98.0) | 21 (100) | 29 (96.7) | 1.000 |
CD4 cell count, median (range) | 506 (94–1843) | 483 (94–1843) | 477 (94–1843) | 488.5 (228–1043) | 0.213 |
Backbone drug | |||||
TAF/FTC, n (%) | 37 (52.1) | 24 (47.1) | 11 (52.4) | 13 (43.3) | 0.578 |
ABC/3TC, n (%) | 29 (40.8) | 22 (43.1) | 8 (38.1) | 14 (46.7) | 0.578 |
TDF/FTC, n (%) | 1 (1.4) | 1 (2.0) | 0 (0) | 1 (3.3) | 1.000 |
NRTI-sparing regimen, n (%) | 4 (5.6) | 4 (7.8) | 2 (9.5) | 2 (6.7) | 1.000 |
Key drug class | |||||
INSTI, n (%) | 59 (83.1) | 41 (80.4) | 17 (81.0) | 24 (80.0) | 1.000 |
NNRTI, n (%) | 7 (9.9) | 5 (9.8) | 2 (9.5) | 3 (10.0) | 1.000 |
PI, n (%) | 1 (1.4) | 1 (2.0) | 0 (0) | 1 (3.3) | 1.000 |
INSTI and PI, n (%) | 4 (5.6) | 4 (7.8) | 2 (9.5) | 2 (6.7) | 1.000 |
Number of non-HIV medications, median (range) | 3 (0–14) | 4 (1–14) | 6 (2–14) | 3 (1–13) | < 0.001 |
Use of ≥5 non-HIV medications, n (%) | 25 (35.2) | 25 (49.0) | 17 (81.0) | 8 (26.7) | < 0.001 |